Short answer
NovoCure Ltd (NVCR) filed an 8-K current report with the SEC on June 5, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Shareholders elected 11 directors, including Asaf Danziger and William Doyle, for terms expiring at the 2027 annual meeting.
NovoCure Ltd 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Shareholders elected 11 directors, including Asaf Danziger and William Doyle, for terms expiring at the 2027 annual meeting
- Board continuity preserved with all elected directors effective immediately
- Directors receive compensation under NovoCure’s non-employee director program
- No disclosed related-party transactions or third-party arrangements involving the elected directors
Item 5.07 · Submission of Matters to a Vote of Security Holders
- 93,826,730 shares represented, equal to approximately 81.01% voting participation
- All eleven director nominees elected through the 2027 annual meeting, with 10,874,130 broker non-votes each
- Kost Forer Gabbay & Kasierer, an Ernst & Young Global member, ratified as fiscal 2026 auditor
- Executive compensation approved on a non-binding advisory basis, with 75,392,168 votes for
- Amended 2024 Omnibus Incentive Plan narrowly approved, 41,680,622 votes for versus 41,161,139 against
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other NovoCure Ltd 8-K filings
Get the next NVCR 8-K as it lands
Follow NVCR for push alerts, or ask the research agent what this filing means.